Mounjaro for weight loss: the licensed indications explained

Step 1, Check whether your BMI clears the licensed threshold

The starting point is straightforward. Pull up the NHS BMI calculator and put your current height and weight in. It takes under a minute. If the result is 30 or above, you sit within the primary licensed indication. If it falls between 27 and 29.9, you are still potentially within scope, but only if you also have at least one weight-related health condition (see Step 2). A result below 27 places you outside the licensed indications entirely, and no legitimate prescriber should offer tirzepatide at that point.

One practical note: BMI thresholds are not one-size-fits-all across every background. UK clinical guidance recognises that for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the risk associated with a given BMI can be higher, so the qualifying thresholds are set 2.5 kg/m² lower. Your prescriber applies the right threshold for you.

Understanding exactly what weight qualifies for Mounjaro is worth reading before you approach any clinic, it covers BMI measurement, weigh-in requirements and what happens if your BMI sits close to a boundary.

Step 2, Identify whether a weight-related condition strengthens your case

If your BMI is 27–29.9, the licensed indication only applies when you also carry at least one weight-related comorbidity. The conditions that count include type 2 diabetes, prediabetes, hypertension, dyslipidaemia (high cholesterol or triglycerides), obstructive sleep apnoea, osteoarthritis and cardiovascular disease. You do not need a formal specialist diagnosis in every case, but you do need evidence the prescriber can review, a GP letter, a recent blood-pressure reading, a lab result.

Even at BMI 30 or above, having a documented comorbidity reinforces the clinical picture. Prescribers are assessing overall health risk, not just a number on a scale. The NICE appraisal of tirzepatide (TA1026) sets out clearly how qualifying conditions factor into NHS recommendations, and those principles shape good private prescribing too.

A full rundown of conditions that count (and some that might surprise you) is covered on the Mounjaro qualifications page, which is worth bookmarking if you are still working out whether you meet criteria.

Step 3, Understand what the indications do not cover

The MHRA licence is specific: weight management alongside a reduced-calorie diet and increased physical activity. Mounjaro is not licensed for cosmetic weight loss. The MHRA has been clear that GLP-1 and dual-agonist medicines are not assessed for quick or appearance-driven purposes, that framing matters when you are assessing whether a clinic is operating legitimately.

There are also medical situations where the licence does not apply regardless of BMI. People who are pregnant, breastfeeding or actively trying to conceive are not suitable candidates. The medicine is not licensed for use in anyone under 18. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) rules it out. So does a history of pancreatitis in certain contexts, something prescribers check specifically. A full list of situations where Mounjaro should not be used is set out on the Mounjaro contraindications page.

It is also worth being clear that Mounjaro for weight loss and Mounjaro for type 2 diabetes share the same molecule but not the same clinical context, the prescriber's assessment covers which licence applies to your situation.

Step 4, How a prescriber turns the indication into a decision about you

Meeting the BMI threshold and having a qualifying condition gets you to the door. What happens inside is a clinical assessment of your whole picture. The prescriber reviews your medical history, current medicines, blood-pressure readings, and any evidence you provide. At nume (sorry, at our pharmacy) that review is done the same day by a named GPhC-registered Independent Prescriber, not by a decision algorithm. Photo-ID and live weight verification are part of the process, and if you are moving across from another clinic, evidence of your current treatment and dose is checked before anything is approved.

If you clear the indications, tirzepatide treatment starts at 2.5mg (a tolerability phase while your system adjusts) with dose increases guided by your prescriber over time. The Mounjaro treatment overview covers the full process from first pen to ongoing review. People considering alternatives, whether because of supply, side-effect profile, or curiosity about how maridebart cafraglutide compares to tirzepatide as an emerging option, may find the Mounjaro alternatives page a useful companion read.

If everything fits clinically, our prescribers can approve treatment the same day and dispatch it via free next-working-day tracked delivery. The place to start is a free consultation, no commitment, just a clinical conversation.